MAPT and Alzheimer disease: Given that APOE is a ligand for HSPG and LDLR and is involved in Aβ aggregation and tau uptake, we investigated the effect of introducing the Christchurch variant (R136S) into mAPOE on development of AD-like pathology, independent of human APOE (hAPOE).